Selected Aspects of Drug use in Renal Failure
The kidney is the major organ involved in the elimination of drugs and their pharmacologically active metabolites. Thus, the frequency and severity of adverse drug reactions are increased in patients with renal insufficiency. Updated recommendations for the use of relevant drugs in patients with varying degrees of renal dysfunction are available (1–3). This paper will review selected aspects of this large subject, emphasizing topics of recent interest and for which new information is available.
KeywordsAutosomal Dominant Polycystic Kidney Disease Cyst Fluid Antibacterial Efficacy Cyst Infection Subcutaneous Abscess
Unable to display preview. Download preview PDF.
- 1.W.M. Bennett, G.R. Aronoff, T.A. Golper, G. Morrison, I. Singer, and D.C. Brater, “Drug Prescribing in Renal Failure: Dosing Guidelines for Adults,” American College of Physicians, Philadelphia (1987).Google Scholar
- 3.D.C. Brater, “Drug Use in Clinical Medicine,” B.C. Decker, Toronto (1987).Google Scholar
- 8.P.J. Ratcliffe, J.W. Sear, QMJ, Hand, and R.A. Moore, Morphine transport in the isolated perfused rat kidney, Proc EDTA-ERA 22:1109–1114 (1985).Google Scholar
- 9.G.L. Chan, G. Matzke, Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opiod analgesics, Drug Intell Clin Pharm 21:773–783 (1937).Google Scholar
- 11.W.M. Bennett, M.N. Hartnett, R. Craven, D.N. Gilbert, and G.A. Porter, Gentamicin concentrations in blood, urine and renal tissue of patients with end-stage renal disease, J Lab Clin Med 30:389–394 (1977).Google Scholar
- 20.S. Schwab, D. Hinthorn, and J.J. Grantham, pH-dependent accumulation of clinamycin in polycystic kidneys. Am J Kidney Pis 3:63–66 (1983).Google Scholar
- 21.W.M. Bennett, T.A. Golper, and L.W. Elzinga, Fluoroquinolones in patients with polycystic kidney disease, Aust NZ J Med (in press).Google Scholar
- 25.W.M. Bennett, G.W. Wood, D.C. Houghton, and D.N. Gilbert, Modification of experimental aminoglycoside nephrotoxicity. Am J Kidney Dis 3:292–296 (1986).Google Scholar
- 26.W.M. Bennett, G.A. Wood, S.J. Kohlhepp, P.W. Kohnen, D.C. Houghton, and D.N. Gilbert, Experimental gentamicin nephrotoxicity can be prevented by polyaspartic acid, Kidnev Int 33:353 (1988).Google Scholar
- 27.G.A. Wood, D.R. Norton, S.J. Kohlhepp, P.W. Kohnen, W.M. Bennett, G.A. Porter, D.C. Houghton, R.E. Brummett, and D.N. Gilbert, The influence of tobramycin dosage regimen on nephrotoxicity, ototoxicity and antibacterial efficacy in a rat model of subcutaneous abscess, J Infect Dis (in press).Google Scholar
- 30.J. Kapusnik, C. Hackbarth, H. Chambers, K. Scott, T. Carpenter, and M. Sande, Efficacy of once daily versus intermittent dosing of tobramycin in neutropenic and normal, sedated guinea pigs with experimental Pseudomonas pneumonia [Abstract 548], in: Program and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, D.C., American Society for Microbiology (1985).Google Scholar